Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytomx Therapeutics, Inc. on February 14, 2022. The filing addresses a change in the Company's executive leadership structure regarding the Chief Financial Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: Carlos Campoy, Chief Financial Officer and Principal Financial Officer, has begun a temporary personal leave of absence. He retains his title and role.
- Interim Appointment: Chris Ogden, Vice President of Finance and Accounting, was designated as the interim Principal Accounting Officer effective February 14, 2022.
- Compensation Details: Mr. Ogden's employment agreement includes an annual base salary of $315,270 and a discretionary annual bonus target of 30% of base salary. His severance and change of control agreement provides for up to nine months of base salary and benefits, plus a prorated bonus.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks and contingencies beyond the standard disclosure of the executive transition. No unusual items were reported.
Investor Verification Checklist
- Verify the duration of Carlos Campoy's temporary leave of absence.
- Confirm the timeline for appointing a permanent Chief Financial Officer.
- Review the Company's most recent 10-K or 10-Q for current liquidity and cash runway, as this 8-K does not contain financial statements.